NGM NGM Biopharmaceuticals Inc.

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Latest News

1. 05 December 2019 NGM Bio Announces Appointment of Shelly Guyer to Board of Directors

   SOUTH SAN FRANCISCO, Calif., Dec. 05, 2019 (GLOBE NEWSWIRE) -- NGM Biopharmaceuticals, Inc. (NASDAQ:NGM), a clinical stage biotechnology company focused on developing transformative therapeutics for patients, today

2. 14 November 2019 NGM Bio to Present at the Stifel 2019 Healthcare Conference

   SOUTH SAN FRANCISCO, Calif., Nov. 14, 2019 (GLOBE NEWSWIRE) -- NGM Biopharmaceuticals, Inc. (NASDAQ:NGM), a clinical stage biotechnology company focused on developing transformative therapeutics for patients, today

3. 12 November 2019 NGM Reports Business Highlights and Third Quarter 2019 Financial Results

   --Announced positive interim results from ongoing 24-week Phase 2 study evaluating-- --1 mg aldafermin (formerly NGM282) (Cohort 4) in non-alcoholic steatohepatitis (NASH) patients--  --Anticipates full Cohort 4 data,

4. 29 October 2019 NGM Bio Announces Appointment of Valerie Pierce as General Counsel

   SOUTH SAN FRANCISCO, Calif., Oct. 29, 2019 (GLOBE NEWSWIRE) -- NGM Biopharmaceuticals, Inc. (NASDAQ:NGM), a clinical stage biotechnology company focused on developing transformative therapeutics for patients, today

5. 18 October 2019 NGM Bio to Present at Upcoming Investor Conferences

   SOUTH SAN FRANCISCO, Calif., Oct. 18, 2019 (GLOBE NEWSWIRE) -- NGM Biopharmaceuticals, Inc. (NASDAQ:NGM), a clinical stage biotechnology company focused on developing transformative therapeutics for patients, today

6. 07 October 2019 NGM Bio Announces Positive Interim Results from Ongoing 24-Week Phase 2 Study Evaluating Aldafermin (NGM282) in Patients with NASH

   --Treatment with aldafermin 1 mg resulted in statistically significant reductions in absolute and relative liver fat at 24 weeks compared to placebo -- -- Statistically significant improvements also observed across key

7. 07 October 2019 NGM Bio Announces Positive Interim Results from Ongoing 24-Week Phase 2 Study Evaluating Aldafermin (NGM282) in Patients with NASH

   --Treatment with aldafermin 1 mg resulted in statistically significant reductions in absolute and relative liver fat at 24 weeks compared to placebo -- -- Statistically significant improvements also observed across key

8. 06 October 2019 NGM Bio to Host Conference Call to Discuss Interim Results from Ongoing 24-Week Phase 2 Study of Aldafermin (NGM282) in Patients with NASH

   SOUTH SAN FRANCISCO, Calif., Oct. 06, 2019 (GLOBE NEWSWIRE) -- NGM Biopharmaceuticals, Inc. (NASDAQ:NGM) will host a conference call and live webcast on Monday, October 7, 2019 at 8:30 a.m. ET (5:30 a.m. PT) to discuss

9. 03 October 2019 NGM Bio Announces Multiple Aldafermin (NGM282) Poster Presentations at Upcoming AASLD's The Liver Meeting®

   SOUTH SAN FRANCISCO, Calif., Oct. 03, 2019 (GLOBE NEWSWIRE) -- NGM Biopharmaceuticals, Inc. (NASDAQ:NGM), a clinical stage biotechnology company focused on harnessing powerful biology to develop transformative